Good morning :)
$
₹
I

IAMBIC+THERAPEUTICS+INC

IAM

US
I

IAMBIC+THERAPEUTICS+INC

IAM

US
$14.793.71% (+0.53)
$
₹
$14.793.71% (+0.53)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $675.9M the stock is ranked 2949

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.69
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Company Profile

Company Profile

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.
Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes technologies, such as Enchant and NeuralPLexer to design and develop small molecule therapeutics. Iambic Therapeutics, Inc. was formerly known as Entos, Inc. and changed its name to Iambic Therapeutics, Inc. in May 2023. The company was incorporated in 2019 and is based in San Diego, California.

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

-44.3
70.3
-38
-4.3
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Revenue
Net Income
Financial YearQ3 2017Q4 2017Q1 2018Q2 2018Q3 2018
Total Revenue00000
Net Income3.22-44.3870.36-38.06-4.31
Net Profit Margin-----
See CostsAll values in $ Thousand

Peers

Price Comparison

Compare IAM with any stocks or ETF

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

  1. IAMBIC+THERAPEUTICS+INC (IAM) share price today is $14.79 as of October 27, 2026 at 12:03 AM IST. The stock touched a day high of $15.14 and a day low of $14.22.

  2. IAMBIC+THERAPEUTICS+INC stock trades on US under the ticker symbol IAM.

  3. IAMBIC+THERAPEUTICS+INC's market capitalization is $675.93M as of October 27, 2026 at 12:03 AM IST.

  4. IAMBIC+THERAPEUTICS+INC's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. IAMBIC+THERAPEUTICS+INC's price-to-book (P/B) ratio is 0 as of October 26, 2026.

  6. Yes, You can buy IAMBIC+THERAPEUTICS+INC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy IAMBIC+THERAPEUTICS+INC shares in three steps: 1. Search IAMBIC+THERAPEUTICS+INC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since IAMBIC+THERAPEUTICS+INC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in IAMBIC+THERAPEUTICS+INC (IAM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6761 shares at the current price of $14.79.

Loading...